Further evidence that would support this hypothesis comes from earlier studies in which ACEI/statins were protective against severe pneumonia, recombinant ACE2 protected mice from lung injury following SARS-CoV infection, and ARBs reduced acute lung injury in rats injected with SARS-CoV S-protein [38, 39]. The gene discussed is ACE2; the disease is severe acute respiratory syndrome.